Switch theme
Sign up to access all valuation multiples
Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America.
2012
2.6K+
LTM Revenue $338M
LTM EBITDA -$116M
$4.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai Junshi has a last 12-month revenue (LTM) of $338M and a last 12-month EBITDA of -$116M.
In the most recent fiscal year, Shanghai Junshi achieved revenue of $249M and an EBITDA of -$131M.
Shanghai Junshi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai Junshi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $338M | XXX | $249M | XXX | XXX | XXX |
| Gross Profit | $266M | XXX | $185M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | -$116M | XXX | -$131M | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -53% | XXX | XXX | XXX |
| EBIT | -$167M | XXX | -$166M | XXX | XXX | XXX |
| EBIT Margin | -49% | XXX | -67% | XXX | XXX | XXX |
| Net Profit | -$156M | XXX | -$164M | XXX | XXX | XXX |
| Net Margin | -46% | XXX | -66% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $49.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shanghai Junshi's stock price is HKD 32 (or $4).
Shanghai Junshi has current market cap of HKD 31.5B (or $4.0B), and EV of HKD 31.5B (or $4.0B).
See Shanghai Junshi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0B | $4.0B | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shanghai Junshi has market cap of $4.0B and EV of $4.0B.
Shanghai Junshi's trades at 16.2x EV/Revenue multiple, and -30.8x EV/EBITDA.
Equity research analysts estimate Shanghai Junshi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai Junshi has a P/E ratio of -28.1x.
See valuation multiples for Shanghai Junshi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV/Revenue | 13.0x | XXX | 16.2x | XXX | XXX | XXX |
| EV/EBITDA | -37.7x | XXX | -30.8x | XXX | XXX | XXX |
| EV/EBIT | -26.2x | XXX | -24.2x | XXX | XXX | XXX |
| EV/Gross Profit | 16.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -28.1x | XXX | -24.6x | XXX | XXX | XXX |
| EV/FCF | -19.4x | XXX | -14.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShanghai Junshi's last 12 month revenue growth is 37%
Shanghai Junshi's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Shanghai Junshi's rule of 40 is -107% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shanghai Junshi's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shanghai Junshi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 37% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -53% | XXX | XXX | XXX |
| EBITDA Growth | -78% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -107% | XXX | -16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 141% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Junshi acquired XXX companies to date.
Last acquisition by Shanghai Junshi was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Junshi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shanghai Junshi founded? | Shanghai Junshi was founded in 2012. |
| Where is Shanghai Junshi headquartered? | Shanghai Junshi is headquartered in Hong Kong. |
| How many employees does Shanghai Junshi have? | As of today, Shanghai Junshi has 2.6K+ employees. |
| Who is the CEO of Shanghai Junshi? | Shanghai Junshi's CEO is Mr. Cong Li. |
| Is Shanghai Junshi publicy listed? | Yes, Shanghai Junshi is a public company listed on HKG. |
| What is the stock symbol of Shanghai Junshi? | Shanghai Junshi trades under 01877 ticker. |
| When did Shanghai Junshi go public? | Shanghai Junshi went public in 2018. |
| Who are competitors of Shanghai Junshi? | Similar companies to Shanghai Junshi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Shanghai Junshi? | Shanghai Junshi's current market cap is $4.0B |
| What is the current revenue of Shanghai Junshi? | Shanghai Junshi's last 12 months revenue is $338M. |
| What is the current revenue growth of Shanghai Junshi? | Shanghai Junshi revenue growth (NTM/LTM) is 37%. |
| What is the current EV/Revenue multiple of Shanghai Junshi? | Current revenue multiple of Shanghai Junshi is 13.0x. |
| Is Shanghai Junshi profitable? | Yes, Shanghai Junshi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shanghai Junshi? | Shanghai Junshi's last 12 months EBITDA is -$116M. |
| What is Shanghai Junshi's EBITDA margin? | Shanghai Junshi's last 12 months EBITDA margin is -34%. |
| What is the current EV/EBITDA multiple of Shanghai Junshi? | Current EBITDA multiple of Shanghai Junshi is -37.7x. |
| What is the current FCF of Shanghai Junshi? | Shanghai Junshi's last 12 months FCF is -$225M. |
| What is Shanghai Junshi's FCF margin? | Shanghai Junshi's last 12 months FCF margin is -67%. |
| What is the current EV/FCF multiple of Shanghai Junshi? | Current FCF multiple of Shanghai Junshi is -19.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
